Company

About

CaroGen

CaroGen

Farmington, Connecticut, United States

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases. Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

CaroGen Corporation

CaroGen Corporation

Hamden, Connecticut, United States

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.

EvolveImmune Therapeutics

EvolveImmune Therapeutics

Branford, Connecticut, United States

At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology.

OncoSynergy

OncoSynergy

Stamford, Connecticut, United States

Our vision: "Cancer treatment in one dose."​ OncoSynergy is a patient-focused biotechnology startup spun out from UCSF and the JLABS South San Francisco incubator. Based in bustling Stamford, Connecticut (~40 mins from NYC), we are creating a new class of cancer medicines to maximize patient survival and quality of life with minimal side effects. We are a small, nimble startup team that launched our first clinical trial in 2020 for glioblastoma (aggressive brain cancer). While we are at the forefront of potential game changing research, please support our patients. They need you to spread awareness far and wide so that more research is being dedicated to devastating cancers like glioblastoma.

Portage Biotech

Portage Biotech

Westport, Connecticut, United States

Portage Biotech is a clinical-stage immuno-oncology company with a team of scientists, clinicians, and pharma-experienced executives who have a long history of success, collectively contributing to five oncology drug approvals. The company is focused on advancing multi-targeted therapies with the mission to expand the number of treatment options for cancer patients.